6,678 trials
Overactive Bladder · Overactive Bladder Syndrome · Urge Incontinence
Primary: Establish Noninferiority of the Single Dose Antibiotic Administration to the Multi-dose Antibiotic Administration. — 1; 1 Participants
Type 2 Diabetes Mellitus · Myocardial Fibrosis · Myocardial Inflammation
Primary: Extracellular Volume Fraction (ECV) — 28.5; 27.7; 28.7; 28.4 Percentage of total tissue volume — p=< 0 .0125
Type 2 Diabetes
Primary: Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline — -2.43; 0.44 percentage — p=<0.024
DENT IMPLANTS · LASER
Primary: Mean Probing Pocket Depth — 4.62; 4.45 millimeters
Post Operative Pain Control
Primary: Overall Benefit Analgesia Score — 4; 5; 3; 3 score on a scale — p=0.75
Major Depression
Primary: Change in Targeted Ventromedial Prefrontal Cortex-Ventral Striatal (vmPFC-VS) Functional Connectivity (FC) — 0.02; -0.13; 0.02; 0.09 Z-score
Chronic Inflammation
Primary: Number of Differentially Expressed Genes — 8.3 Differentially expressed genes
Acne
Primary: Percent Change From Baseline in Total Lesions at Week 12 — -17.1; -45.6; -13.0; 7.6 Percent change in lesions
Hospitalization · Infection
Primary: Hospital Transfers Due to Infection — 1243; 1780 Transfers — p=<0.001
Essential Fatty Acid Deficiency (EFAD)
Primary: Number of Participants to Develop Essential Fatty Acid Deficiency (EFAD) Defined by Holman Index > 0.4 — 0; 0 Participants
Thyroid Diseases
Primary: Thyroid Difficulty Scale Score — 9.8; 9.75 score on a scale
Syphilis
Primary: The Number of Participants With a Serological Response by Month 6. — 94; 87 Participants — p=0.002
Diabetes
Primary: Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline — 0; 0 participants
Surgery · Coronary Artery Disease
Primary: Time to Extubation — 10.4; 6 Minutes
Sepsis · AKI · Neurotoxicity
Primary: Acute Kidney Injury (AKI) Ordinal Scale — 910; 952; 86; 100 Participants